| 2024 | 2023 | 2022 | ||||||||||
| A$’000 | A$’000 | A$’000 | ||||||||||
| Profit/(loss) before income tax | 56,056 | 3,087 | (98,622) | |||||||||
| Prima-facie tax at a rate of 30.0% (2023: 30.0%, 2022: 30.0% ) | 16,817 | 926 | (29,587) | |||||||||
| Tax effect of amounts which are not deductible (taxable) in calculating taxable income: | ||||||||||||
| Net R&D tax incentive credit | (20,939) | (7,408) | (6,688) | |||||||||
| Remeasurement of provisions | 7,441 | 13,915 | 7,423 | |||||||||
| Share-based payments expense | 153 | 2,636 | 2,434 | |||||||||
| Employee Share Trust payments | (2,124) | (10,776) | (8,073) | |||||||||
| Sundry items | 562 | 569 | 2 | |||||||||
| Foreign exchange translation loss | - | 1,028 | (464) | |||||||||
| 1,910 | 890 | (34,953) | ||||||||||
| Current year tax losses not recognized | 61,409 | 35,152 | 46,325 | |||||||||
| Prior year tax losses recognized | - | - | (854) | |||||||||
| Adjustment for current tax of prior periods | - | - | 561 | |||||||||
| Difference in overseas tax rates | (57,182) | (38,166) | (5,622) | |||||||||
| Income tax (benefit)/expense | 6,137 | (2,124) | 5,457 | |||||||||
| 2024 | 2023 | 2022 | ||||||||||
| A$’000 | A$’000 | A$’000 | ||||||||||
| Therapeutics | ||||||||||||
| TLX591 (Phase 3) | 44,879 | 23,975 | 15,518 | |||||||||
| TLX250, TLX101 (Phase 2) | 12,404 | 10,441 | 8,241 | |||||||||
| TLX66, TLX300 (Phase 1) | 10,900 | 4,534 | 1,605 | |||||||||
| Pre-clinical research and innovation | 14,399 | 8,616 | 7,038 | |||||||||
| Total Therapeutics R&D | 82,582 | 47,566 | 32,402 | |||||||||
| Precision Medicine | ||||||||||||
| Illuccix, TLX591-CDx (Commercial) | 14,725 | 10,565 | 10,611 | |||||||||
| Pixclara, Zircaix, Gozellix (Pre-commercial) | 88,754 | 59,605 | 31,667 | |||||||||
| Pre-clinical research and innovation | 7,869 | 10,157 | 6,007 | |||||||||
| Total Precision Medicine R&D | 111,348 | 80,327 | 48,285 | |||||||||
| Total product development R&D | 193,930 | 127,893 | 80,687 | |||||||||
| Manufacturing Solutions | ||||||||||||
| Other research and development projects | 707 | 644 | - | |||||||||
| Total Manufacturing Solutions R&D | 707 | 644 | - | |||||||||
| Total research and development costs | 194,637 | 128,537 | 80,687 | |||||||||
| Due < 1 year | Due > 1 year | |||||||
| A$’000 | A$’000 | |||||||
| At December 31, 2024 | ||||||||
| Capital commitments1 | 42,679 | 22,502 | ||||||
| R&D commitments | 30,151 | 7,620 | ||||||
| 72,830 | 30,122 | |||||||
| December 31, 2023 | ||||||||
| Capital commitments | 16,572 | 40,000 | ||||||
| R&D commitments | 28,112 | 20,403 | ||||||
| 44,684 | 60,403 | |||||||
| <1 | 1-3 | 3-5 | >5 | ||
| Total | year | years | years | years | |
| A$ | A$ | A$ | A$ | A$ | |
| (in thousands) | |||||
| Capital commitments | 65,181 | 42,679 | 22,247 | 255 | - |
| R&D commitments | 37,771 | 30,151 | 7,620 | - | - |
| 2024 | 2023 | 2022 | ||||||||||||||
| Note | A$’000 | A$’000 | A$’000 | |||||||||||||
| Cash flows from operating activities | ||||||||||||||||
| Receipts from customers | 718,135 | 463,654 | 124,095 | |||||||||||||
| Receipts in relation to R&D tax incentive | - | - | 18,909 | |||||||||||||
| Payments to suppliers and employees | (642,537) | (414,079) | (204,289) | |||||||||||||
| Payments for contingent consideration | (35,886) | (16,282) | - | |||||||||||||
| Income taxes paid | (2,809) | (10,253) | (2,278) | |||||||||||||
| Interest received | 10,856 | 1,629 | 1 | |||||||||||||
| Interest paid | (4,730) | (785) | (408) | |||||||||||||
| Net cash from/(used in) operating activities | 31.1 | 43,029 | 23,884 | (63,970) | ||||||||||||
| Cash flows from investing activities | ||||||||||||||||
| Payments for investments in financial assets | (51,988) | (13,155) | - | |||||||||||||
| Payments for acquisition of subsidiaries, net of cash acquired | (30,890) | - | (973) | |||||||||||||
| Purchases of intangible assets | (19,710) | (1,115) | (6,823) | |||||||||||||
| Purchases of other non-current assets | (14,459) | - | - | |||||||||||||
| Purchases of property, plant and equipment | (14,322) | (9,679) | (7,038) | |||||||||||||
| Payments for contingent consideration | (3,804) | (1,484) | - | |||||||||||||
| Payments for decommissioning liability | - | (56) | (2,163) | |||||||||||||
| Net cash used in investing activities | (135,173) | (25,489) | (16,997) | |||||||||||||
| Cash flows from financing activities | ||||||||||||||||
| Proceeds from borrowings | 655,938 | 5,756 | 3,014 | |||||||||||||
| Repayment of borrowings | (1,115) | - | (13) | |||||||||||||
| Principal element of lease payments | (2,015) | (2,222) | (1,264) | |||||||||||||
| Proceeds from issue of shares and other equity | 999 | 6,652 | 181,039 | |||||||||||||
| Transaction costs of borrowings or capital raising | (14,884) | - | (7,816) | |||||||||||||
| Net cash provided by financing activities | 638,923 | 10,186 | 174,960 | |||||||||||||
| Net increase in cash held | 546,779 | 8,581 | 93,993 | |||||||||||||
| Net foreign exchange differences | 40,330 | (1,673) | 299 | |||||||||||||
| Cash and cash equivalents at the beginning of the financial year | 123,237 | 116,329 | 22,037 | |||||||||||||
| Cash and cash equivalents at the end of the financial year | 710,346 | 123,237 | 116,329 | |||||||||||||
